Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC
online resourceposted on 2022-02-23, 06:56 authored by James E. Frampton
The Entrectinib in NTRK+ Solid Tumours and ROS1+ NSCLC Adis Drug Evaluation video abstract, script and image slide deck provide a brief overview of the mechanism of action of entrectinib in NTRK+ solid tumours and ROS1+ NSCLC, the administration regimen and the key efficacy and tolerability outcomes from clinical trials.
The video abstract, script and slide deck, which have been peer reviewed and were uploaded to Figshare after the Entrectinib in NTRK+ Solid Tumours and ROS1+ NSCLC Adis Drug Evaluation was published, are sponsored by F. Hoffmann-La Roche.
The video abstract can be found here.
© Springer Nature Switzerland AG 2022